期刊文献+

不同密度口服阳性对比剂对PET/CT图像质量及标准摄取值的影响 被引量:3

Impact on the PET image quality and standard uptake value with positive oral contrast agents
下载PDF
导出
摘要 目的探讨不同密度口服阳性对比剂对PET/CT图像质量和标准摄取值(SUV)的影响。方法60例PET/CT显像患者,显像前常规口服浓度为2%的泛影葡胺1000ml,其中14例患者肠道内发现多处高密度残留钡剂。所有患者均同时采用CT及137Cs两种衰减校正方法,分别重建CT衰减校正(CTAC)、137Cs衰减校正(CsAC)图像。选择所有患者胃肠道内泛影葡胺充盈区、无对比剂充盈区、臀部软组织区以及14例患者高密度钡剂充盈区勾划感兴趣区(ROI)。比较各感兴趣区CTAC和CsAC的平均SUV差异,以及CTAC、CsAC的图像差异。结果在所有正常软组织区、无对比剂充盈区以及泛影葡胺充盈区,CTAC和CsAC的平均SUV无显著性差异。在高密度残留钡剂充盈区,CTAC的平均SUV明显高于CsAC(t=3.451,P=0.018),其差异与CT值成正相关(r=0.445,P=0.021)。比较所有图像,正常软组织、无对比剂充盈区、泛影葡胺充盈区CTAC和CsAC图像质量无明显差异。在高密度残留钡剂充盈区,CTAC图像上可见FDG高摄取伪影,而CsAC图像为正常摄取。结论低密度口服泛影葡胺对PET/CT显像图像质量和标准摄取值无明显影响,高密度钡剂可使PET/CT的SUV明显高估,且可出现不同程度的FDG高摄取伪影。 Objective To evaluate the impact of orally take low-density meglumine and high-density barium on the PET image quality and standard uptake value(SUV).Methods Sixty patients underwent PET/CT on the Gemini system.All orally took 2% meglumine 1000 ml before imaging,and high-density barium in abdomen was found in 14 patients.CT attenuation correction(CTAC)and ^137Cs attenuation correction(CsAC)images were reconstructed respectively.Regions of interest(ROI)of the bowel that full of meglumine and barium,no contrast region and the buttocks muscle region were drawn respectively in all patients.Then the image quality and SUV from the CTAC images were compared with those from the CsAC images.Results The values of SUV from the normal soft tissues,meglumine regions and no contrast regions were not statistically different between the CTAC and CsAC methods,while the average SUVs of CTAC images were objectively higher than that of the CsAC ones in barium regions(t=3.451,P=0.018).Image quality of normal soft tissue,meglumine regions and no contrast regions from CTAC and CsAC respectively had no obviously difference.The image artifact was obvious in the barium region with CTAC method and no artifact in the same regions with CsAC method.Conclusion This study showed that low-density meglumine has no obvious impact to the image quality and SUV,but SUVs might be high-estimated and the image artifacts may develop in the high-density barium regions.
出处 《中国医学影像技术》 CSCD 北大核心 2008年第12期1999-2001,共3页 Chinese Journal of Medical Imaging Technology
关键词 体层摄影术 发射型计算机 对比剂 Tomography,emission-computed Contrast media
  • 相关文献

参考文献12

  • 1朱朝晖.PET-CT技术的发展现状与展望[J].现代仪器,2004,10(4):6-11. 被引量:30
  • 2孙龙,吴华,官泳松.PET/CT与低剂量CT诊断T1期肺癌[J].中国介入影像与治疗学,2007,4(3):232-235. 被引量:3
  • 3孙龙,吴华,官泳松,潘为民,刘源,胡颖,拉孜.PET/CT在放射性粒子组织间种植治疗恶性实体肿瘤[J].中国介入影像与治疗学,2006,3(3):231-234. 被引量:8
  • 4陈钊,郑容,吴宁.^(18)F-FDG PET-CT的主要局限性和相应处理措施[J].中国医学影像技术,2006,22(2):320-323. 被引量:12
  • 5Kinahan PE, Hasegawa BH, Beyer T. X-ray-based attenuation correction for Positron emission tomography/computed tomography scanners. Semin Nucl Med, 2003,33(3) : 166-179.
  • 6Dizendorf E, Hany TF, Buck A, et al. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med, 2003, 44 (5) : 732-738.
  • 7Antoch G, Freudenherg LS, Beyer T, et al. To enhance or not to enhance? ^18F-FDG and CTcontrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med, 2004,45(S1) :56S-65S.
  • 8Yau YY, Chan WS, Tam YM, et al. Application of intravenous contrast in PET/ CT: does it really introduce significant attenuation correction error? J Nuc Med, 2005,46(2):283-291.
  • 9Groves AM, Kayani I, Dickson JC, et al. Oral contrast medium in PET/ CT : should you or shouldn' t you? Eur J Nucl Med Mol Imaging, 2005,32(10) : 1160-1166.
  • 10Nakamoto Y, Chin BB, Kraitchman DL, et al. Effects of nonion ie intravenous contrast agents at PET/PCT imaging: phantom and canine studies. Radiology, 2003,227(3) :817-824.

二级参考文献54

  • 1Toru Ishikawa,Hiroteru Kamimura,Atsunori Tsuchiya,Tadayuki Togashi,Kouji Watanabe,Kei-ichi Seki,Hironobu Ohta,Toshiaki Yoshida,Noriko Ishihara,Tomoteru Kamimura.Comparison of a new aspiration needle device and the Quick-Core biopsy needle for transjugular liver biopsy[J].World Journal of Gastroenterology,2006,12(39):6339-6342. 被引量:4
  • 2[1]Hu J,Galeone C,Lui R,et al.Smoking and lung cancer in Harbin,northeast China.Ann Oncol,2005,16(10):1605-1608.
  • 3[2]Guo X,Cui Z.Current diagnosis and treatment of pancreatic cancer in China.Pancreas,2005,31(1):13-22.
  • 4[3]He XW,Wu H.The progress of cancer targeted radioiodine therapy.Radiol Practice (Chinese),2005,20(1):87-90.
  • 5[4]Merrick GS,Butler WM,Galbreath RW,et al.Five year biochemical outcome following permanent interstitial brachytherapy for clini2 cal T1~T3 prostate cancer.Int J Radiat Oncol Biol Phys,2001,51(1):41-48.
  • 6[5]Williamson JF,Coursey BM,DeWerd LA,et al.Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry:implications for specification and prescription.Med Phys,2000,27(4):634-642.
  • 7[6]Nag S,Ciezki JP,Cormack R,et al.Intraoperative planning and evaluation of permanent prostate brachytherapy:report of the American Brachytherapy Society.Int J Radiat Oncol Biol Phys,2001,51(5):1422-1430.
  • 8[7]Chen A,Galloway M,Landreneau R,et al.Intraoperative 125I brachytherapy for high risk stage I non-small cell lung carcinoma.Int J Radiat Oncol Biol Phys,1999,44(5):1057-1063.
  • 9[8]Merrick GS,Butler WM,Galbreath RW,et al.Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ confirmed carcinoma of the prostate gland.Int J Radiat Oncol Biol Phys,2002,52(3):664-673.
  • 10[9]Yue L.Implantation with 125 I seeds for the treatment of tumor.Foreign Medical Sciences,Section of Radiation Medicine and Nuclear Medicine,2001,25(1):23-26

共引文献49

同被引文献19

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部